Varian’s IDE win makes way for first ever FLASH therapy clinical trial
By Nikita Chaurasia  Date: 2020-10-13

Varian’s IDE win makes way for first ever FLASH therapy clinical trial

U.S.-based radiotherapy technology company, Varian Medical Systems has made it to the headlines for reportedly receiving an IDE (Investigational Device Exemption) from the U.S. Food & Drug Administration.

For the uninitiated, FLASH therapy is an innovative radiation treatment that involves ultra-high dose rates of radiotherapy. The study, named FAST-01, will conduct the investigation using Varian's ProBeam particle accelerator which is apparently modified with a specialized module with FLASH capabilities.

If reports are to be believed, the trial will involve over 10 patients with bone metastases and evaluate parameters such as side-effects, efficacy of the treatment and clinical workflow feasibility. In fact, preclinical trials conducted by Varian suggested that the new technology is significantly faster and causes lesser tissue damage as compared to conventional radiotherapy.

It is to be noted that Varian has supported the FlashForward Cosortium, a 20-member group of institutions from across the globe, that includes experts in translational sciences, radiation oncology and medical physics.

Speaking of the trials, President of Proton Therapy Solutions and Chief Growth Officer at Varian, Kolleen Kennedy, was reported saying that the company’s advancement in FLASH therapy is a testament to their investments and efforts towards improving cancer treatment.

Dr. Deepak Khuntia, Chief Medical Officer and Senior VP of Varian mentioned in a comment that the investigation is vital proof of concept, particularly in deep-seated as well as superficial tumors. It will impart a thorough understanding regarding the operations of FLASH therapy , he added.

Sources close to the matter claim that the patient enrollment in the FAST-01 Feasibility Study is expected to commence by the end of the year 2020.

About Varian Medical Systems

California-headquartered Varian Medical Systems is a radiation oncology treatments and software company and focuses on developing innovative cancer care technologies and solutions.

With over 10,000 employees across 70 locations, the company harnesses advanced technologies such as machine learning, AI (artificial intelligence) and data analytics in order to enhance cancer treatment.

 

Source credits: https://www.prnewswire.com/news-releases/varian-receives-investigational-device-exemption-ide-and-prepares-for-first-ever-clinical-trial-of-flash-therapy-301149339.html

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Mayo Clinic Laboratories forms alliance with American Hospital Dubai
Mayo Clinic Laboratories forms alliance with American Hospital Dubai
By Nikita Chaurasia

In recent developments, Minnesota-based Mayo Clinic Laboratories and American Hospital Dubai are reportedly planning on entering a strategic alliance which is aimed at enhancing advanced laboratory diagnostic services in Dubai. Under the terms of th...

LTI, IBM extend global partnership to spearhead digital transformation
LTI, IBM extend global partnership to spearhead digital transformation
By Nikita Chaurasia

The New York-headquartered IBM Corp., with its global partner Larsen Toubro Infotech, an Indian global IT solutions & services company, are planning to extend their multi-year partnership, in a bid to enable companies to revolutionize the busines...

Algae cultivator Qualitas Health raises USD 10 million in funding round
Algae cultivator Qualitas Health raises USD 10 million in funding round
By Nikita Chaurasia

In recent developments, privately held food and nutrition company Qualitas Health Inc. has reportedly secured USD 10 million in venture funds, as it looks to broaden the reach of its plant-based protein and omega-3 business. The company was appraised...

China touts plans of launching national ETS to attain carbon neutrality
China touts plans of launching national ETS to attain carbon neutrality
By Nikita Chaurasia

According to reliable sources, the Chinese government is expected to launch the much anticipated national emission trade scheme (ETS) by mid-2021 as a part of the country’s efforts of achieving carbon-neutrality by the year 2060, through market...

Fujifilm to develop large-scale cell culture manufacturing site in U.S.
Fujifilm to develop large-scale cell culture manufacturing site in U.S.
By Nikita Chaurasia

In a bid to proliferate its biopharmaceutical contract development and manufacturing business, Fujifilm Corporation is reportedly planning to invest around USD 2 billion (200 billion yen) towards the development of a large-scale cell culture manufact...